tiprankstipranks
Trending News
More News >

Bluejay Diagnostics Initiates SYMON-II Clinical Study

Story Highlights
  • Bluejay Diagnostics is advancing its SYMON-II clinical study and plans a 510(k) submission for its IL-6 test by 2027.
  • The company raised $3.8 million in April 2025 and is reducing its workforce to extend its cash runway.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Bluejay Diagnostics Initiates SYMON-II Clinical Study

Don’t Miss TipRanks’ Half-Year Sale

An update from Bluejay Diagnostics ( (BJDX) ) is now available.

On June 3, 2025, Bluejay Diagnostics provided a mid-year business update, highlighting the initiation of the pivotal SYMON-II clinical study following the successful SYMON-I pilot study. The company is progressing towards a 510(k) submission for its Symphony IL-6 test by the fourth quarter of 2027, aiming for FDA approval by the third quarter of 2028. Bluejay is also addressing manufacturing challenges by collaborating with SanyoSeiko and exploring third-party manufacturing options. Financially, the company reported $5.7 million in cash as of April 30, 2025, and raised $3.8 million in April through private placement. To extend its cash runway, Bluejay has reduced its workforce and is seeking additional funding. The upcoming annual meeting on June 18, 2025, will address board restructuring and stock split proposals to maintain Nasdaq listing compliance.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.

Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which offers rapid, near-patient testing solutions for sepsis triage and monitoring. Their primary product candidate is the IL-6 Test, designed to provide quick and reliable results to aid medical professionals in making timely treatment decisions.

Average Trading Volume: 1,209,781

Technical Sentiment Signal: Sell

Current Market Cap: $2.63M

Find detailed analytics on BJDX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1